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Available treatments for neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease, do not
arrest disease progression but mainly help keeping patients from getting worse for
a limited period of time. Increasing evidence suggests that epigenetic mechanisms
such as DNA methylation and histone tail modifications are dynamically regulated in
neurons and play a fundamental role in learning and memory processes. In addition,
both global and gene-specific epigenetic changes and deregulated expression of the
writer and eraser proteins of epigenetic marks are believed to contribute to the onset
and progression of neurodegeneration. Studies in animal models of neurodegenerative
diseases have highlighted the potential role of epigenetic drugs, including inhibitors
of histone deacetylases and methyl donor compounds, in ameliorating the cognitive
symptoms and preventing or delaying the motor symptoms of the disease, thereby
opening the way for a potential application in human pathology.
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INTRODUCTION
Epigenetic processes, including DNA methylation and post-
translational modifications of the histone tails, influence gene
expression levels without involving changes of the primary DNA
sequence, and play a fundamental role in embryonic develop-
ment, cell differentiation, andmaintenance of the cellular identity
(Martín-Subero, 2011). They are also dynamically regulated in
neurons in response to experiential stimuli to regulate the expres-
sion of memory-related genes, and play a role in the formation,
consolidation and storage of memory (Guo et al., 2011a; Puckett
and Lubin, 2011; Sultan and Day, 2011; Lattal and Wood, 2013).
Therefore, it is not surprising that changes of epigenetic marks
might be at least partially involved in the onset and progression of
neurodegenerative diseases (Coppedè, 2014), leading researchers
to hypothesize that targeting the epigenome with compounds
exerting epigenetic properties could represent a promising
preventative and therapeutic approach for neurodegeneration
(Karagiannis and Ververis, 2012; Harrison and Dexter, 2013).
DNA METHYLATION
DNAmethylation typically occurs in CpG islands (regions unusu-
ally enriched in the CpG dinucleotide, found in the promoter
region of almost a half of human genes and relatively absent
from most other places in the genome) and consists of the addi-
tion of a methyl group (CH3) to the 5′ position of the cytosine
pyrimidine ring, forming 5-methylcytosine (5-mC). The reac-
tion is mediated by DNA methyltransferases (DNMTs) using
S-adenosylmethionine (SAM) as the methyl donor compound.
Methylation of CpG islands in the promoter region of a gene
can be specifically recognized by a set of proteins called methyl-
CpG binding proteins (MBPs), that contain a transcription
repression domain to interact with other proteins and enhance
DNA methylation-mediated transcriptional repression (Fournier
et al., 2012; Jones, 2012). Enzymes of the TET (ten-eleven
translocation) family promote DNA demethylation converting 5-
methylcytosine to 5-hydroxymethylcytosine (5-hmc), a modified
form of cytosine hydroxymethylated at the 5′ position showing
lower affinity for MBPs and present at high levels in the brain
(Guo et al., 2011b).
HISTONE TAIL MODIFICATIONS
The nucleosome is the structural and functional unit of chro-
matin and consists of approximately 147 DNA base pairs wrapped
twice around a histone octamer consisting of two copies each
of the core histones H2A, H2B, H3, and H4. Nucleosomes are
connected by stretches of “linker DNA” and linker histones,
such as histone H1, and are involved in chromatin compaction
(Luger et al., 1997). Histone tail modifications include acetyla-
tion, methylation, phosphorylation, ubiquitylation, sumoylation
and other post-translational modifications (Berger, 2007). The
combination of those modifications, and their crosstalk with
DNA methylation and chromatin remodeling proteins, regulate
the chromatin structure in a dynamic fashion. Indeed, chromatin
can exist in a condensate inactive state (heterochromatin) or in a
non-condensate and transcriptionally active state (euchromatin)
(Berger, 2007).
Acetylation and methylation of the histone tails repre-
sent the two most studied mechanisms of histone modifica-
tions. Acetylation of lysine residues on histone tails neutralizes
their positive charge and decreases their affinity for the DNA,
leading to an increased accessibility of transcriptional regula-
tory proteins to chromatin templates. Histone acetyltransferases
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(HATs) and deacetylases (HDACs) catalyze lysine acetylation
and deacetylation, respectively (Berger, 2007). Eighteen HDAC
enzymes are known in mammals which are divided into four
classes (I-IV). A summary of their function and localization is
provided in Table 1, more detailed information can be found
in recent research and review articles (Broide et al., 2007;
Zakhary et al., 2010; Joshi et al., 2013; Lazo-Gómez et al., 2013).
Methylation on either lysine or arginine residues of the histone
tails can be associated with either condensation or relaxation of
the chromatin structure, since several sites for methylation are
present on each tail thus allowing different combinations (Martin
and Zhang, 2005). Crosstalk between acetylation andmethylation
at specific residues further influences transcriptional activation,
for example di- and tri-methylation of H3K4 (H3K4me2 or
H3K4me3), and acetylation at H3/H4 (H3K9Ac andH4K9Ac) are
generally linked to an open chromatin structure that allows gene
transcription, while histone hypoacetylation, and tri-methylation
at H3K9 (H3K9me3) and H3K27 (H3K27me3) are consid-
ered repressive marks (Berger, 2007). Histone methyltransferases
(HMTs) transfer the methyl group from SAM to histone tail
residues, and histone demethylases (HDMTs) are the “erasers” of
that mark (Martin and Zhang, 2005).
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder and the primary form of dementia in the elderly.
Table 1 | Mammalian histone deacetylase (HDAC) proteins and some of their inhibitors (HDACi).
Histone deacetylase (HDAC) class/function Proteins/sub-cellular localization/brain and
spinal cord regions of expression*
HDAC inhibitors (HDACi)
Class I
(Zinc dependent)
Involved in: regulation of gene-specific
transcription through the formation of stable
transcriptional complexes
HDAC 1/nucleus/Ce, Ob, A, Hi, Co, Ch, P, Sc, Hy,
Sn-c, Sn-r, M, Na, Cp
HDAC 2/nucleus/Hi, Ce, Ob, Co, A, CP, Na, P, Sc,
Sn-c, Hy, M, Sn-r
HDAC 3/shuttle between nucleus and
cytoplasm/Hi, Ce, Ob, Co, A, Sn-c, Hy, Cp, Na,
Ch, M, Sc, P, Sn-r, Gp
HDAC 8/nucleus / Hi, Ce, Ob, A, Sn-c, Co, Hy, P,
M, Sc
Pan-inhibitors: trichostatin A, vorinostat,
butyrate, phenylbutyrate, valproate
Selective inhibitors: MS-275 (HDAC1), 4b
(HDAC1 and 3)
Class IIa
(Zinc dependent)
Shuttle between nucleus and cytoplasm to
interact with both nuclear and cytoplasmic
proteins, have histone deacetylase activity by
interacting with HDAC3
HDAC 4/nucleus-cytoplasm/Ce, Hi, Ob, Co, A,
Sn-c, Hy, P, M, Sc, Sn-r, Na, Cp, Gp
HDAC 5/nucleus-cytoplasm/Ce, Hi, Ob, Co, Sn-c,
Hy, Cp, Na, A, P, M, Sc, Ch, Sn-r, Gp
HDAC 7/nucleus-cytoplasm/Ce, Hi, Ob, A, Sn-c,
Co, Cp, Na, Hy, P, M, Sc
HDAC 9/nucleus-cytoplasm/Hi, Sn-c, Ob, Co, A,
P, Ce
Pan-inhibitors: trichostatin A, vorinostat,
butyrate, phenylbutyrate, valproate
Class IIb
(Zinc dependent)
HDAC6: take part in the microtubule network by
acting on α-tubulin and tau proteins, and plays a
fundamental role in the formation of protein
aggregates; HDAC10: cytoplasmic deacetylase
HDAC 6/cytoplasm/Hi, Ob, Ce, Co, A, Sn-c, Hy, P,
Cp, Na, M, Sc
HDAC 10/cytoplasm/Hi, Ob, Ce, A
Pan-inhibitors: Trichostatin A, vorinostat
Class III
(nicotinamide dependent)
SIRT 1-3 have robust deacetylase activity; SIRT4
is an ADP-ribosyltransferase; SIRT 5 has
deacetylase and other activities; SIRT 6 has
ADP-ribosyl transferase and deacetylase
activities; SIRT 7 is a deacetylase
Sirtuin (SIRT) 1 and 6/nucleus/(SIRT 1) Co, Hi,
Ce, Hy, Sc
SIRT 2/cytosol
SIRT 3, 4, 5/mitochondria
SIRT 7/nucleolus
Pan-inhibitor: nicotinamide
Selective inhibitors: AK-1, AGK-2, AK-7 (sirtuin 2)
Class IV
(Zinc dependent)
Member of the survival of motor neuron
complex, has a functional role in mRNA splicing
HDAC 11/nucleus/Hy, A, Ob, P, Co, Cp, Na, Hi,
Sn-c, Sc, M, Sn-r, Gp
LAQ824
*Expression levels are obtained from studies in brain regions of rodents (Broide et al., 2007; Zakhary et al., 2010) and ordered from high expression (first) to low
expression (latter). A, amygdala; Ce, cerebellum; Ch, choroid plexus; Co, cortex; Cp, caudate putamen; Gp, globus pallidus; Hi, hippocampus; Hy, hypothalamus; Na,
nucleus accumbens; M, medulla; Ob, olfactory bulb; P, pons; Sc, spinal cord; Sn-c, Substantia nigra pars compacta; Sn-r, Substantia nigra pars reticulata.
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The disease symptoms get worse over time and available treat-
ments may only help keeping patients from getting worse for a
short period. Affected brain regions show extracellular amyloid
deposits called senile plaques (SP) and intra-neuronal aggre-
gates of hyperphosphorylated tau protein, called neurofibrillary
tangles (NFT). The primary component of SP is the amyloid
β (Aβ) peptide, resulting from the proteolytic cleavage of its
precursor protein (APP), mediated by the proteins β-secretase
(BACE1) and γ-secretase, a protein complex composed of prese-
nilins and other proteins (Overk andMasliah, 2014).Mutations in
APP and presenilin (PSEN1 and PSEN2) genes cause early-onset
(<65 years) AD, overall accounting for almost 1% of the cases.
However, most of AD (95–98%) are late-onset (>65 years) spo-
radic forms, resulting from complex interactions among genetic,
environmental and stochastic factors superimposed on the physi-
ological decline of cognitive functions with age (Coppedè, 2014).
Epigenetic mechanisms are at the core of gene-environment inter-
actions and believed to play a role in AD (Migliore and Coppedè,
2009).
Particularly, DNA methylation changes in AD are supported
by studies in cell cultures and animal models (reviewed in
Coppedè, 2014), by a number of studies that have shown reduced
global levels of 5-mC and 5-hmC in human post-mortem AD
brains (Mastroeni et al., 2010; Chouliaras et al., 2013), and by
recent epigenome-wide approaches searching for candidate genes
(Bakulski et al., 2012; Sanchez-Mut et al., 2014). Also changes in
histone tail modifications have been observed in post-mortem
AD brains, including decreased levels of H3 acetylation in the
temporal lobe (Zhang et al., 2012), and increased levels of the
histone deacetylases HDAC6 and HDAC2, the first leading to
increased tau phosphorylation and the latter repressing genes
required for learning and memory (Ding et al., 2008; Gräff et al.,
2012). However, studies in humans are scarce, limited by the
small sample size of case and control brains, and often conflict-
ing (Coppedè, 2014; Coppieters et al., 2014). Those performed
with rodents and cell cultures revealed the contribution of histone
modifications to learning and memory processes, and the manip-
ulation of histone acetylation with HDAC inhibitors (HDACi) in
AD animal models often resulted in both prevention of cognitive
deficits and memory recovery (Karagiannis and Ververis, 2012).
EPIGENETIC INTERVENTIONS IN ALZHEIMER’S DISEASE
Folate, other B group vitamins (B2, B6, and B12), and homocys-
teine (hcy), participate in one-carbon metabolism, the metabolic
pathway required for SAM production, and there is indication of
impaired one-carbon metabolism and reduced DNAmethylation
potential in AD individuals (Coppedè, 2010). Human neuroblas-
toma cells and transgenic AD mice maintained under conditions
of B vitamin deficiency showed PSEN1 promoter demethylation,
with subsequent increased production of presenilin1, BACE1
and APP proteins, and Aβ deposition in the animal brains. By
contrast, SAM supplementation induced an opposite tendency,
restored PSEN1 methylation levels, and reduced the progression
of the AD-like features induced by B vitamin deficiency in
mice (Fuso et al., 2005, 2008, 2012). There is some indication
from elderly human subjects suggesting that B vitamin supple-
mentation can slow the atrophy of specific brain regions that
are associated with cognitive decline, but additional trials are
warranted to see if the progression to dementia can be prevented
(Douaud et al., 2013). In addition, dietary SAM supplementation
reduced oxidative stress (Tchantchou et al., 2008) and delayed
Aβ and tau pathology in transgenic AD mice (Lee et al., 2012),
suggesting a possible role of SAM as a neuroprotective dietary
supplement in AD.
Another line of active research involves the manipulation
of histone acetylation with HDACi in AD animal models
(Karagiannis and Ververis, 2012). Several inhibitors of those
enzymes have been developed, including valproic acid, tricho-
statin A, sodium phenylbutyrate, and vorinostat that interact
with zinc-dependent HDAC proteins (class I, class II, and
class IV), nicotinamide that inhibits class III HDACs, and
more recent compounds that selectively inhibit certain HDACs
(Table 1). Early studies in the field revealed that sodium butyrate
administration for 4 weeks was able to reinstate learning and
memory in transgenic mice that already suffered from severe
AD pathology (Fischer et al., 2007). Subsequent studies revealed
that sodium butyrate injection in a transgenic mouse model
of AD is correlated with decreased tau phosphorylation and
restoration of dendritic spine density in hippocampal neurons
(Ricobaraza et al., 2010), and prolonged treatment in a transgenic
mouse model for amyloid deposition (APP/PS1 mice) improved
associative memory by increasing both hippocampal histone
acetylation and the expression of genes implicated in associative
learning (Govindarajan et al., 2011). Others showed that after
fear conditioning training, the levels of hippocampal acetylated
histone 4 (H4) in APP/PS1 mice were about 50% lower than
in wild-type littermates. However, an acute treatment with
trichostatin A prior to training rescued both acetylated H4
levels and contextual freezing performances to wild-type values
(Francis et al., 2009). Several similar examples are available in the
literature concerning HDACi andmemory function in AD animal
models, for example 2–3 weeks treatment with either sodium
valproate, sodium butyrate, or vorinostat reversed contextual
memory deficits in APP/PS1 mice (Kilgore et al., 2010), a 10
days treatment with entinostat, a selective inhibitor of HDAC1,
reduced neuroinflammation and amyloid plaque deposition and
improved behavioral impairment in APPPS1-21 mice (Zhang
and Schluesener, 2013), and a 4 week treatment with a class II
inhibitor in transgenic AD mice over-expressing mutant APP,
presenilin1 and tau proteins (3 × AD mice), improved memory
functions and decreased Aβ and phosphorylated tau levels (Sung
et al., 2013). Taken overall, those studies suggest that targeting
histone modifications with HDACi can improve cognition and
reduce AD-like features in AD models (Table 2).
PARKINSON’S DISEASE
Parkinson’s disease (PD), the second most common neurodegen-
erative disorder after AD, is clinically characterized by resting
tremor, rigidity, bradykinesia, and postural instability as well
as non-motor symptoms such as autonomic insufficiency, cog-
nitive impairment, and sleep disorders. Pathologically, PD is
characterized by progressive and profound loss of neuromelanin
containing dopaminergic neurons in the substantia nigra with
the presence of eosinophilic, intracytoplasmic inclusions called
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Table 2 | Some examples of the effects of histone deacetylase inhibitors (HDACi) in animal models of neurodegenerative diseases.
Compound Experimental model* Results References
Sodium butyrate Transgenic AD mice (CK-p25) 4 week intra-peritoneal administration
improved learning and memory
Fischer et al., 2007
Trichostatin A Transgenic AD mice (APP/PS1) Acute treatment prior to fear conditioning
training rescued hippocampal H4 acetylation
levels and contextual freezing performances
Francis et al., 2009
Sodium butyrate, sodium
valproate, or vorinostat
Transgenic AD mice (APP/PS1) 2–3 weeks intra-peritoneal injection reversed
contextual memory deficits
Kilgore et al., 2010
Sodium butyrate Transgenic AD mice (APP/PS1) Chronic intra-peritoneal injection improved
associative memory
Govindarajan et al., 2011
Sodium butyrate Transgenic AD mice (Tg2576) 5 week intra-peritoneal injection decreased tau
phosphorylation and restored dendritic spine
density in hippocampal neurons
Ricobaraza et al., 2010
MS-275 (entinostat) Transgenic AD mice (APP/PS1) 10 days oral administration ameliorated
neuroinflammation and cerebral amyloidosis
and improved behavior
Zhang and Schluesener, 2013
W2 (Class II HDACi) Transgenic AD mice (3 × AD) 4 weeks intra-peritoneal injection improved
memory functions and decreased Aβ and
phosphorylated tau levels
Sung et al., 2013
Sodium butyrate or vorinostat Drosophila model of PD
overexpressing α-synuclein
20 days treatment reduced α-synuclein
mediated toxicity
Kontopoulos et al., 2006
AK-1 or AGK-2 (sirtuin 2 HDACi) Drosophila model of PD
overexpressing α-synuclein
20 days treatment reduced α-synuclein
mediated toxicity
Outeiro et al., 2007
Valproic acid Rotenone-induced PD rat model 4 weeks oral administration counteracted
α-synuclein nuclear translocation and toxicity
Monti et al., 2010
Sodium butyrate MPTP-induced PD mouse
model
14 days oral administration up-regulated DJ-1
expression and reduced neurotoxicity
Zhou et al., 2011
Sodium butyrate Rat model of PD 5 days intra-peritoneal injection alleviated
cognitive deficits
Rane et al., 2012
Sodium butyrate Rotenone-induced PD fly model 3 days oral administration improved locomotor
impairment and early mortality
St Laurent et al., 2013
Sodium butyrate, trichostatin A,
or valproate
ALS mice (SOD1-G93A) Several studies show that treatments with one
ot those agents delayed disease progression
and/or increased animal survival
Sugai et al., 2004; Ryu et al.,
2005; Yoo and Ko, 2011
4b (HDAC1i and HDAC3i) Transgenic HD mice 10–12 weeks injections improved motor
functions and elicited cognitive decline
Jia et al., 2012
AK-7 (sirtuin 2 HDACi) Transgenic HD mice 4 weeks intra-peritoneal injection improved
motor functions, extended survival and
reduced mutant huntingtin aggregation
Chopra et al., 2012
*Most of the used transgenic models over-expressed mutant proteins (amyloid precursor protein and presenilin 1 in AD APP/PS1 models, α-synuclein in PD
models, mutant superoxide dismutase “SOD1” in ALS models, and mutant huntingtin in HD model) or were induced by pesticide exposure (such as rotenone
or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine “MPTP”). AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; HD, Huntington’s disease; PD, Parkinson’s
disease).
Lewy bodies (LBs; containing aggregates of α-synuclein and other
substances), and Lewy neurites in surviving neurons. Although
some improvements of the symptoms can be achieved with
levodopa and dopaminergic therapy, there is no available treat-
ment to halt disease progression (Thomas and Beal, 2011). The
majority of PD cases are sporadic, likely arising from a combi-
nation of polygenic inheritance, environmental exposures, and
complex gene-environment interactions superimposed on slow
and sustained neuronal dysfunction due to aging (Migliore and
Coppedè, 2009). In a minority of the cases PD is inherited as a
Mendelian trait, and studies in PD families allowed the identi-
fication of at least 15 PD loci (PARK1-15) and several causative
genes (Nuytemans et al., 2010). Most of the studies evaluating
the role of epigenetics in disease pathogenesis have focused on
the analysis of promoter methylation of causative PD genes in
post-mortem brains and peripheral blood cells of affected indi-
viduals (Coppedè, 2012). Particularly, reduced methylation levels
of the gene coding for α-synuclein (SNCA gene), the first identi-
fied causative PD gene, were observed in several brain regions of
sporadic PD patients including the substantia nigra (Jowaed et al.,
2010; Matsumoto et al., 2010). In addition, it was shown that
α-synuclein sequesters DNMT1 from the nucleus into the cyto-
plasm, and reducedDNMT1 levels were observed in post-mortem
PD brains (Desplats et al., 2011).
Our knowledge of histone modifications in PD derives mainly
from studies in cell cultures and animal models of the disease,
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such as those induced by the mitochondrial toxins 1-methyl-
4-phenylpyridinium (MPP+), paraquat and rotenone, or those
overexpressing human α-synuclein (Harrison and Dexter, 2013).
Overall, those studies revealed that α-synuclein interacts with his-
tones and inhibits histone acetylation, and that several HDACi are
neuroprotective against α-synuclein-mediated toxicity (Table 2).
EPIGENETIC INTERVENTIONS IN PARKINSON’S DISEASE
The analysis of nigral neurons of mice exposed to the herbicide
paraquat revealed that α-synuclein translocates into the nucleus
and binds to histones (Goers et al., 2003). Studies in Drosophila
showed that α-synuclein mediates neurotoxicity in the nucleus,
binds directly to histone H3, and inhibits histone acetylation.
The toxicity of α-synuclein was rescued by the administration
of sodium butyrate or vorinostat (Kontopoulos et al., 2006).
Selective inhibition of the histone deacetylase sirtuin 2 rescued
α-synuclein-mediated toxicity in several models of PD (Outeiro
et al., 2007). In addition, valproic acid resulted neuroprotective in
a rotenone-induced rat model of PD counteracting α-synuclein
translocation into the nuclei (Monti et al., 2010). Neurotoxic pes-
ticides and paraquat were shown to increase histone acetylation in
mice brains or cell culturemodels (Song et al., 2010, 2011), and an
increasing number of studies reveal protective effects of HDACi
on neurons following a neurotoxic-induced insult (Harrison and
Dexter, 2013). For example, it was recently shown that tricho-
statin A selectively rescues mitochondrial fragmentation and cell
death induced by MPP+ in human neuroblastoma cells (Zhu
et al., 2014), and that sodium butyrate improves locomotor
impairment and earlymortality in a rotenone-inducedDrosophila
model of PD (St Laurent et al., 2013), alleviates cognitive deficits
in a rat model of PD in the pre-motor deficit stage (Rane et al.,
2012), and up-regulates DJ-1 protein expression and protects
neurons in cell cultures andmouse models against MPP+ toxicity
(Zhou et al., 2011). DJ-1 is involved in the protection of oxidative
stress, and mutation of DJ-1 gene cause early-onset PD (Bonifati
et al., 2003).
All the above studies suggest that histone modifications occur
in α-synuclein-mediated as well as environmentally-induced
dopaminergic neuronal cell death and suggest a protective role
for HDACi in those models (Table 2).
OTHER NEURODEGENERATIVE DISEASES
Several similar examples of the potential neuro-protective effects
obtained by targeting the epigenome are available for other
neurodegenerative diseases than AD or PD. For example, SAM
supplementation in a transgenic mouse model (SOD1-G93A) of
amyotrophic lateral sclerosis (ALS) delayed the onset of motor
neuron pathology (Suchy et al., 2010). Also HDACi amelio-
rated disease progression in ALS animal models. For example,
sodium phenylbutyrate significantly extended survival in G93A
transgenic ALS mice (Ryu et al., 2005). The combination of
phenylbutyrate and riluzole ameliorated gross lumbar and ven-
tral horn atrophy, attenuated lumbar ventral horn neuronal cell
death, and decreased reactive astrogliosis in ALS G93A mice (Del
Signore et al., 2009). Similarly, combined lithium and valproate
treatment delayed disease onset, reduced neurological deficits and
prolonged survival (Feng et al., 2008), and treatment with tricho-
statin A (Yoo and Ko, 2011), or valproate (Sugai et al., 2004),
delayed disease progression and/or increased survival in the
SOD1-G93A mice. A phase II study in ALS individuals revealed
that sodium phenylbutyrate was safe and tolerable, and histone
acetylation was significantly increased after sodium phenylbu-
tyrate administration (Cudkowicz et al., 2009). Conversely, a trial
using valproic acid did not show a beneficial effect on survival or
disease progression in patients with ALS (Piepers et al., 2009).
Research in Huntington’s disease (HD), a neurodegenerative
diseases caused by trinucleotide repeat expansion in the gene
(HTT) coding for the huntingtin protein, revealed that mutant
huntingtin directly interacts with HAT proteins, leading to altered
histone acetylation (Steffan et al., 2000; Jiang et al., 2006).
Numerous studies revealed that treatment with HDACi arrested
the ongoing progressive neuronal degeneration in both fly and
mouse models of HD (reviewed by Gray, 2010). Some recent
examples using selective HDACi are listed in Table 2 (Chopra
et al., 2012; Jia et al., 2012), and other compounds are under
investigation (Bürli et al., 2013; Duan, 2013).
CONCLUDING REMARKS
The studies described in this manuscript provided evidence that
targeting the epigenome, mainly with small drugs such as HDACi
that are able to cross the blood brain barrier, delayed the onset
and progression of the symptoms in animal models of neurode-
generative disease (Table 2). Several other examples are available
in the literature, but cannot be described in details due to limited
space allowance.
Despite the encouraging results obtained so far in animalmod-
els, highlighting the potential of HDACi for the treatment of
neurodegenerative diseases, additional research is required prior
to their application to humans. Indeed, as suggested by many
authors, reasons of concern include the multi-targeted and multi-
cellular effects exerted by most of those drugs, the possibility of
unexpected side effects, and the anatomical and metabolic dif-
ferences between humans and rodents, suggesting that further
investigation is warranted to clarify the most appropriate thera-
peutical approaches, including the use of pan-HDACi or selective
inhibitors, the timing, the dosage regimen, a better understand-
ing of the interplay among histone tail modifications and other
mechanisms that regulate gene expression, and the evaluation
of potential side effects (Harrison and Dexter, 2013; Fischer,
2014). In addition, the mode of delivery varied among studies,
and not all HDACs are similarly expressed in the brain regions
affected by AD, PD, or other neurodegenerative diseases (Table 2).
Indeed, albeit HDAC2 and HDAC6 could represent promising
drug targets in AD, it remains unknown which drug or dos-
ing regime present the most efficacy, and similar conclusions
can be drawn for other neurodegenerative diseases (Harrison
and Dexter, 2013; Fischer, 2014). Moreover, not all drugs always
work. For example, valproic acid treatment in the SOD1 trans-
genic ALS mice only prevented motor neuron death, but failed
to improve survival or motor performance (Rouaux et al., 2007),
and similar results were observed in the clinical trial in humans
(Piepers et al., 2009). Another limitation to our knowledge is
that drugs have been tested in animal models bearing muta-
tions in human genes, such as SOD1, that only account for only
about 1–2% of the total human cases (Table 2). Moreover, other
writer or eraser proteins of the histone code than HDACs could
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represent potential targets for drug development, but studies are
scarce (Fischer, 2014), and natural compounds found in the diet,
including folate, vitamins, polyphenols, and flavonoids, alter the
availability of methyl groups and influence the activity of DNMTs,
thereby representing potential “epigenetic” preventive factors for
neurodegeneration (Coppedè, 2014).
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